Today on Stinchfield, we take on one of the most explosive medical debates in America right now. What if two cheap, widely available drugs—Ivermectin and Mebendazole—could play a role in fighting cancer?

A groundbreaking study highlighted by The Wellness Company is raising serious questions about whether these long-used medications may have powerful anti-cancer properties. We’re talking about drugs that have been around for decades, with established safety profiles, now being looked at as potential disruptors in one of medicine’s most lucrative industries.

So why isn’t this front-page news everywhere? Why aren’t billions being poured into fast-tracking this research? Critics argue it’s because there’s no profit in cures that cost next to nothing. Meanwhile, patients and doctors searching for alternatives are left to dig through emerging data and early-stage studies on their own.

We break down what the science actually says, where the evidence stands today, and what’s still unknown. Is this a real breakthrough… or another case of hope racing ahead of proof? And most importantly, who decides what treatments get attention—and what gets buried?

🔔 SUPPORT OUR SPONSORS

https://Twc.Health/Grant (code “Grant” for 10% off)